Senior Writer, Medicine, and Editorial Director, Events
Matthew Herper is a senior writer at STAT, where he covers medicine and oversees the editorial portion of STAT’s events. With two decades of experience, he focuses on medical innovation, pharmaceuticals, and healthcare, exploring both their promises and challenges. He has been featured in RealClearHealth, STAT News, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Matthew Herper's coverage primarily focuses on the healthcare and pharmaceutical sectors, with an emphasis on data-driven insights and industry announcements. His articles frequently cite data, incorporate press releases, and feature private sector announcements.
Given his extensive use of data in reporting, he may be particularly interested in sources who can provide statistical analysis or empirical evidence related to developments in pharmaceuticals, medical research, cancer treatment, gene editing, or drug development.
He does not appear to have a specific geographic focus but provides comprehensive coverage of global trends within the healthcare and pharmaceutical industries. When reaching out to him with pitches or expert commentary offers it should align with these thematic areas for higher chances of engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Even if the biggest claims about the technology are hype, it may still have an immediate impactThe most convincing thing Dario Amodei, the CEO and
By: Matthew Herper, Jason Mast
How a father’s quest may shape the future of rare disease gene therapy.
By: Jason Mast, Matthew Herper
A father's $70 million pursuit of a gene therapy has implications for an entire field Highlights
By: Elaine Chen, Matthew Herper
Regulators at the Food and Drug Administration have reiterated concerns that Replimune does not have adequate data to support an approval of its investigational skin cancer treatment, as the biotech tries for the third time to seek clearance for its highly controversial drug.
By: Matthew Herper, Elaine Chen
Panel's deliberations are key for company — and could signal the agency's broader posture
Trump's call to overhaul how the shots are administered introduces major public health risks
By: Angus Chen, Matthew Herper
Results could herald a new, powerful approach in other cancers A personalized mRNA cancer vaccine, added to an existing treatment, slowed
By: Matthew Herper, Angus Chen
Results could herald a new, powerful approach in other cancers. This story is republished from STAT , the health and medicine news site that's a partner to the Globe.
By: Matthew Herper, Angus Chen, Jason Mast
The drugmakers overcame rampant doubts, logistical challenges, and the pandemic
Is it the ‘secret sauce' in the cancer vaccine co-developed with Merck?
